We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CME Stock Nears 52-Week Low After a 19.8% Drop: Time to Hold or Exit?
Read MoreHide Full Article
Key Takeaways
CME posted record non-U.S. ADV of 11.4M contracts, with growth across APAC and EMEA.
CME is expanding its equity and crypto derivatives offerings, including four new E-mini contracts.
CME returned about $3.2B to shareholders in Q1 2026 and maintained a strong cash position.
Shares of CME Group, Inc. (CME - Free Report) have declined 19.8% over the past three months, compared with the industry’s drop of 9.7%, pushing the stock near its 52-week low of $ 244.56. The company’s share price closed at $246.38 on Thursday.
The stock has been weighed down by concerns over its premium valuation, competitive threats, and selling pressure as investors locked in gains after a strong rally earlier this year. Investor sentiment has also been affected by the recent leadership transition announcement. However, its dominant derivatives franchise, robust profitability and strong cash-generation capabilities suggest that the recent pullback may present a potential opportunity for investors.
Shares of some of its peers, like Cboe Global Markets, Inc. (CBOE - Free Report) , Deutsche Borse AG (DBOEY - Free Report) and Intercontinental Exchange, Inc. (ICE - Free Report) , fell 12.2%, 0.7% and 15.5%, respectively, in the past three months.
Image Source: Zacks Investment Research
CME’s Average Target Price Suggests Upside
Based on short-term price targets offered by 15 analysts, the Zacks average price target is $308.80 per share. The average suggests a potential 22.3% upside from the last closing price.
Image Source: Zacks Investment Research
CME’s Valuation
CME Group is currently trading at a premium. Its forward price-to-earnings (P/E) ratio is 19.67X, which is above the industry average of 19.04X.
Image Source: Zacks Investment Research
CME’s Growth Projection Encourages
The Zacks Consensus Estimate for CME Group’s 2026 earnings per share (EPS) indicates a year-over-year increase of 9.6%. The consensus estimate for revenues is pegged at $7.05 billion, implying a year-over-year improvement of 8.1%.
The consensus estimate for 2027 EPS and revenues indicates an increase of 4.3% and 4.7%, respectively, from the corresponding 2026 estimates.
Optimistic Analyst Sentiment for CME
Two analysts have raised estimates for 2026, while one analyst has increased estimates for 2027, with no downward movement over the past 30 days. Thus, the Zacks Consensus Estimate for 2026 and 2027 earnings has moved north 0.2% and south 0.3%, respectively, over the same period.
What Drives CME’s Growth?
CME Group continues to invest in electronic functionality, pricing and connectivity to keep the platform competitive, which should help CME capture activity during volatile markets and across time zones, including from customers outside the United States. It also makes it easier for clients to trade complex spread options electronically.
The company continues to expand across regions, with record non-U.S. ADV of 11.4 million contracts and strong growth across APAC and EMEA. Alongside futures growth in emerging markets, CME’s over-the-counter offerings, market data and information services, and cross-selling through alliances and acquisitions should continue to support top-line momentum.
CME has extended its exclusive Nasdaq futures license through 2029, ensuring continued access to the Nasdaq product suite for its clients. Importantly, BrokerTec Chicago is gaining traction as clients leverage smaller tick sizes and co-location alongside CME’s core futures markets. These efforts strengthen links between cash and futures markets and support incremental transaction, clearing and data revenues. CME’s cryptocurrency derivatives expansion is another avenue for growth as the product set and client adoption mature.
CME Group recently unveiled four new E-mini contracts in a bid to broaden its benchmark suite of Equity Index Futures. The products are scheduled to launch on June 29. The move underscores the company’s strategy to strengthen its equity index ecosystem and address growing demand for broad-market risk management tools.
CME Group maintains a solid liquidity position. As of March 31, 2026, the company had $2.6 billion in cash. It held long-term debt of $3.4 billion. This strong balance sheet supports steady capital returns and enhances investor confidence.
A strong capital-return strategy remains a key positive for CME. The company returned roughly $3.2 billion to shareholders in the first quarter of 2026 through dividends and share repurchases. Moreover, its dividend yield of 2.1% exceeds the industry average of 1.4%, making the stock attractive to income-focused investors.
Risks for CME
CME Group’s diversified product portfolio is significantly exposed to interest-rate volatility, currency fluctuations, strict government regulation and shifting liquidity conditions.
CME faces intense competition from exchanges, trading venues and emerging market participants. Regulatory changes and the increasing adoption of crypto-based trading platforms could heighten competitive pressures and weigh on future trading volumes.
Expenses have risen in recent periods as a result of higher compensation and benefits, technology spend, professional fees, and depreciation and amortization. It expects adjusted operating expenses excluding license fees to be approximately $1.695 billion in 2026.
Conclusion
CME Group's diverse derivative product lines, strong global presence, OTC offerings, cross-selling through alliances, and rising electronic trading should drive growth. It delivers solid profitability, steady growth and reliable dividends. However, rising competition, currency fluctuations and higher expenses could put pressure on future growth.
View the Zacks #1 Rank List
Image: Bigstock
CME Stock Nears 52-Week Low After a 19.8% Drop: Time to Hold or Exit?
Key Takeaways
Shares of CME Group, Inc. (CME - Free Report) have declined 19.8% over the past three months, compared with the industry’s drop of 9.7%, pushing the stock near its 52-week low of $ 244.56. The company’s share price closed at $246.38 on Thursday.
The stock has been weighed down by concerns over its premium valuation, competitive threats, and selling pressure as investors locked in gains after a strong rally earlier this year. Investor sentiment has also been affected by the recent leadership transition announcement. However, its dominant derivatives franchise, robust profitability and strong cash-generation capabilities suggest that the recent pullback may present a potential opportunity for investors.
Shares of some of its peers, like Cboe Global Markets, Inc. (CBOE - Free Report) , Deutsche Borse AG (DBOEY - Free Report) and Intercontinental Exchange, Inc. (ICE - Free Report) , fell 12.2%, 0.7% and 15.5%, respectively, in the past three months.
Image Source: Zacks Investment Research
CME’s Average Target Price Suggests Upside
Based on short-term price targets offered by 15 analysts, the Zacks average price target is $308.80 per share. The average suggests a potential 22.3% upside from the last closing price.
Image Source: Zacks Investment Research
CME’s Valuation
CME Group is currently trading at a premium. Its forward price-to-earnings (P/E) ratio is 19.67X, which is above the industry average of 19.04X.
Image Source: Zacks Investment Research
CME’s Growth Projection Encourages
The Zacks Consensus Estimate for CME Group’s 2026 earnings per share (EPS) indicates a year-over-year increase of 9.6%. The consensus estimate for revenues is pegged at $7.05 billion, implying a year-over-year improvement of 8.1%.
The consensus estimate for 2027 EPS and revenues indicates an increase of 4.3% and 4.7%, respectively, from the corresponding 2026 estimates.
Optimistic Analyst Sentiment for CME
Two analysts have raised estimates for 2026, while one analyst has increased estimates for 2027, with no downward movement over the past 30 days. Thus, the Zacks Consensus Estimate for 2026 and 2027 earnings has moved north 0.2% and south 0.3%, respectively, over the same period.
What Drives CME’s Growth?
CME Group continues to invest in electronic functionality, pricing and connectivity to keep the platform competitive, which should help CME capture activity during volatile markets and across time zones, including from customers outside the United States. It also makes it easier for clients to trade complex spread options electronically.
The company continues to expand across regions, with record non-U.S. ADV of 11.4 million contracts and strong growth across APAC and EMEA. Alongside futures growth in emerging markets, CME’s over-the-counter offerings, market data and information services, and cross-selling through alliances and acquisitions should continue to support top-line momentum.
CME has extended its exclusive Nasdaq futures license through 2029, ensuring continued access to the Nasdaq product suite for its clients. Importantly, BrokerTec Chicago is gaining traction as clients leverage smaller tick sizes and co-location alongside CME’s core futures markets. These efforts strengthen links between cash and futures markets and support incremental transaction, clearing and data revenues. CME’s cryptocurrency derivatives expansion is another avenue for growth as the product set and client adoption mature.
CME Group recently unveiled four new E-mini contracts in a bid to broaden its benchmark suite of Equity Index Futures. The products are scheduled to launch on June 29. The move underscores the company’s strategy to strengthen its equity index ecosystem and address growing demand for broad-market risk management tools.
CME Group maintains a solid liquidity position. As of March 31, 2026, the company had $2.6 billion in cash. It held long-term debt of $3.4 billion. This strong balance sheet supports steady capital returns and enhances investor confidence.
A strong capital-return strategy remains a key positive for CME. The company returned roughly $3.2 billion to shareholders in the first quarter of 2026 through dividends and share repurchases. Moreover, its dividend yield of 2.1% exceeds the industry average of 1.4%, making the stock attractive to income-focused investors.
Risks for CME
CME Group’s diversified product portfolio is significantly exposed to interest-rate volatility, currency fluctuations, strict government regulation and shifting liquidity conditions.
CME faces intense competition from exchanges, trading venues and emerging market participants. Regulatory changes and the increasing adoption of crypto-based trading platforms could heighten competitive pressures and weigh on future trading volumes.
Expenses have risen in recent periods as a result of higher compensation and benefits, technology spend, professional fees, and depreciation and amortization. It expects adjusted operating expenses excluding license fees to be approximately $1.695 billion in 2026.
Conclusion
CME Group's diverse derivative product lines, strong global presence, OTC offerings, cross-selling through alliances, and rising electronic trading should drive growth. It delivers solid profitability, steady growth and reliable dividends. However, rising competition, currency fluctuations and higher expenses could put pressure on future growth.
Despite near-term headwinds, CME's dominant market position, favorable growth estimates, optimistic analyst sentiment and dividend history support a hold stance on this Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.